Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Short position
Neuren Pharmaceuticals (ASX:NEU) has 2.95% of its shares on issue reported as short positions as of 5 Oct 2026, or about 3,735,393 shares. Over the past 30 days that figure has fallen 0.08 percentage points, and over 90 days it has fallen 1.96 percentage points. Its highest recorded short interest was 6.51% in June 2026. NEU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Neuren Pharmaceuticals (NEU) financials
Results, ratios and statements
Latest result
12 months to 30 Jun 2026 (TTM Jun 26) vs TTM Jun 25, figures in AUD, the reporting currency
- Revenue
- $69.5Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- $20.3Mvs n/a (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- $0.15vs $1.14 (TTM Jun 25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- −69.7%FY
- EPS YoY
- −86.5%TTM
Key ratios
12 months to 30 Jun 2026 (TTM); balance sheet at 31 Dec 2025, 6 months before; prices to 9 Oct 2026
- Gross margin
- 100.0%
- Operating margin
- 19.9%
- Net margin
- 29.1%
- FCF margin
- 7.3%
- ROE
- 5.8%
- ROA
- 5.4%
- FCF conversion
- 0.25×
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 76.6×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $2.56B
- P/E
- 130.9×
- P/B
- 7.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | TTM Jun 26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | $69.5M | $64.6M | $213.2M | $231.9M | $14.6M |
| Gross profit | $69.5M | $64.6M | $213.2M | $231.9M | $14.6M |
| Operating income | $13.8M | $22.0M | $175.6M | $199.2M | −$1.6M |
| EBITDA | $13.8M | $22.0M | $175.6M | $199.2M | −$1.6M |
| EBIT | $13.8M | $22.0M | $175.6M | $199.2M | −$1.6M |
| Pretax income | $26.8M | $38.9M | $182.9M | $205.1M | $184.0K |
| Tax | $6.6M | $8.5M | $40.9M | $48.1M | $0 |
| NPAT | $20.3M | $30.4M | $142.0M | $157.1M | $184.0K |
| Net interest income | $11.4M | $12.2M | $11.0M | $5.7M | $391.0K |
| EPS basic | $0.16 | $0.24 | $1.11T (source: Derived: trailing 12 months at year end) | $1.24 | $0.002 |
| EPS diluted | $0.15 | $0.23 | $1.09 | $1.20 | $0.002 |
| Shares | n/a | 126.6M | 129.3M | 129.7M | 129.0M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Half Yearly Report and AccountsHalf Year Results26 Aug 2026via asx_announcements
- Neuren H1 2026 Financial Results Webinar on 26 August 2026Financial Report21 Aug 2026via asx_announcements
- 2025 Annual Report to shareholdersAnnual Report24 Apr 2026via asx_announcements
- Appendix 4E and 2025 full year accountsAnnual Results27 Feb 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results27 Aug 2025via asx_announcements
- 2024 Annual Report to shareholdersAnnual Report3 Apr 2025via asx_announcements
- Appendix 4E and 2024 full year accountsAnnual Results28 Feb 2025via asx_announcements
- 2024 Full Year Results webinarFull Year Results28 Feb 2025via asx_announcements
- Half Yearly Report and AccountsHalf Year Results27 Aug 2024via asx_announcements
- H1 2024 financial resultsFinancial Report27 Aug 2024via asx_announcements
Showing 10 of 89 reports